| HOME >> BIOLOGY >> TECHNOLOGY |
CAMBRIDGE, Mass., Feb. 13 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: VRNM), a leading developer of cellulosic ethanol technology and a pioneer in the development of high-performance specialty enzymes, announced today that John A. McCarthy, Jr., Verenium's Executive Vice President and Chief Financial Officer, will present at the upcoming Piper Jaffray Clean Technology & Renewables Conference. The presentation is scheduled to begin at 10:00 a.m. ET on Wednesday, February 20, and will take place at the New York Palace Hotel in New York, NY.
More information about this event, including a live webcast, may be accessed by visiting the "Investors" section of Verenium's website at http://www.verenium.com. A webcast replay will be available approximately one hour after the live webcast ends and will be accessible for one month following the conference.
About Verenium
Verenium Corporation is a leader in the development and commercialization of cellulosic ethanol, an environmentally-friendly and renewable transportation fuel, as well as high-performance specialty enzymes for applications within the biofuels, industrial, and health and nutrition markets. The Company possesses integrated, end-to-end capabilities in pre-treatment, novel enzyme development, fermentation, engineering, and project development and is moving rapidly to commercialize its proprietary technology for the production of ethanol from a wide array of feedstocks, including sugarcane bagasse, dedicated energy crops, agricultural waste, and wood products. In addition to the vast potential for biofuels, a multitude of large-scale industrial opportunities exist for the Company for products derived from the production of low-cost, biomass-derived sugars.
Verenium's Specialty Enzyme business harnesses the power of enzymes to create a broad range of specialty products to meet high-value commercial needs. Verenium's world class R&D organization is renowned for its capabilities in the rapid screening, identification, and expression of enzymes-proteins that act as the catalysts of biochemical reactions.
Verenium operates one of the nation's first cellulosic ethanol pilot plants, an R&D facility, in Jennings, Louisiana and expects to achieve mechanical completion of a 1.4 million gallon-per-year, demonstration-scale facility to produce cellulosic ethanol by the end of the first quarter of 2008. In addition, the Company's process technology has been licensed by Tokyo-based Marubeni Corp. and Tsukishima Kikai Co., LTD and has been incorporated into BioEthanol Japan's 1.4 million liter-per-year cellulosic ethanol plant in Osaka, Japan -- the world's first commercial-scale plant to produce cellulosic ethanol from wood construction waste. For more information on Verenium, visit http://www.verenium.com.
Forward Looking Statements
Statements in this press release that are not strictly historical are
"forward-looking" and involve a high degree of risk and uncertainty. These
include statements related to the Company's operations, capabilities,
commercialization activities, target markets and cellulosic ethanol
facilities, all of which are prospective. Such statements are only
predictions, and actual events or results may differ materially from those
projected in such forward-looking statements. Factors that could cause or
contribute to the differences include, but are not limited to, risks
associated with Verenium's new and uncertain technologies, risks associated
with Verenium's dependence on patents and proprietary rights, risks
associated with Verenium's protection and enforcement of its patents and
proprietary rights, technological, regulatory, competitive and other risks
related to development, production, and commercialization of cellulosic
ethanol and other biofuels and the commercial prospects of those
industries, Verenium's dependence on existing collaboration, manufacturing,
and/or license agreements, and its ability to achieve milestones under
existing and future collaboration agreements, the ability of Verenium and
its partners to commercialize products (including by obtaining any required
regulatory approvals) using Verenium's technologies and timing for
launching any commercialized products, the ability of Verenium and its
collaborators to market and sell any products that it or they
commercialize, the development or availability of competitive products or
technologies, the future ability of Verenium to enter into and/or maintain
collaboration and joint venture agreements and licenses, changes in the
U.S. or global energy markets and risks and other uncertainties more fully
described in the Company's filings with the Securities and Exchange
Commission, including, but not limited to, the Company's quarterly report
on Form 10-Q for the quarter ended September 30, 2007. These
forward-looking statements speak only as of the date hereof. The Company
expressly disclaims any intent or obligation to update these
forward-looking statements.
Contact:
Verenium Corporation
Kelly Lindenboom
Vice President, Corporate Communications
617-674-5335
'/>"/>
| SOURCE Verenium Corporation Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Verenium Explores Bacterial Genes Inside Termite Guts to Understand How Wood is Broken Down and Converted to Energy
2. Verenium Corporation to Present at the Pacific Growth Equities 2007 Clean Technology & Industrial Growth Conference
3. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
4. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
5. VLST Corporation Announces Board and Executive Management Appointments
6. AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II
7. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
8. LifeCell Corporation Revises Full Year 2007 Preliminary Results and Schedules Fourth Quarter 2007 Financial Results Conference Call; February 27, 2008 at 10:00 a.m. Eastern
9. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
10. Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy
11. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |